Mitobridge, Inc, 1030 Massachusetts Avenue, Cambridge, MA 02138, United States.
Mitobridge, Inc, 1030 Massachusetts Avenue, Cambridge, MA 02138, United States.
Mitochondrion. 2019 May;46:51-58. doi: 10.1016/j.mito.2018.02.006. Epub 2018 Feb 16.
Duchenne muscular dystrophy (DMD) is a recessive, fatal X-linked disease that is characterized by progressive skeletal muscle wasting due to the absence of dystrophin, which is an a essential protein that bridges the inner cytoskeleton and extra-cellular matrix. This study set out to characterize the mitochondria in primary muscle satellite cell derived myoblasts from mdx mice and wild type control mice. Compared to wild type derived cells the mdx derived cells have reduced mitochondrial bioenergetics and have fewer mitochondria. Here, we demonstrate that a novel PPARδ modulator improves mitochondrial function in the mdx mice, which supports that modulating PPARδ may be therapeutically beneficial in DMD patients.
杜氏肌营养不良症(DMD)是一种隐性、致命的 X 连锁疾病,其特征是由于缺乏肌营养不良蛋白而导致进行性骨骼肌消耗,肌营养不良蛋白是一种将细胞内骨架和细胞外基质连接起来的必需蛋白。本研究旨在描述来自 mdx 小鼠和野生型对照小鼠的原代肌肉卫星细胞衍生成肌细胞中的线粒体。与野生型细胞相比,mdx 衍生的细胞线粒体生物能量降低,线粒体数量减少。在这里,我们证明了一种新型的 PPARδ 调节剂可改善 mdx 小鼠的线粒体功能,这支持了调节 PPARδ 在 DMD 患者中可能具有治疗益处。